Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125441 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL3174249 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL219711 | 0.96 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Bromide SCHEMBL221648 | 0.96 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Sulfuric Acid SCHEMBL28341061 | 0.88 | NPC1 (0.58) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydroxyamphetamine SCHEMBL7041719 | 0.81 | TAAR1 (0.66) | SIGMAR1TAAR1SLC18A2SLC6A4 | |
| Methamphetamine SCHEMBL27438559 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL30624762 | 0.79 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL21243273 | 0.79 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL2958028 | 0.78 | SLC6A4 (0.63) | SIGMAR1TAAR1SLC6A4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| EP-1480677-B1 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2012-02-29 | — | — | EP | claimed |
| US-8088789-B2 | Administering hemiketal ring and seco-macrocyclic lactones; immunosuppressive, anti-proliferative, anti-fungal and anti-tumor | ELIXIR MEDICAL CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| EP-2352459-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2011-08-10 | — | — | EP | claimed |
| EP-2254412-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | US | claimed |
| WO-2010040064-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | WO | claimed |
| WO-2009114010-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2008-09-25 | — | — | US | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| US-12458532-B2 | Multi-dose ocular fluid delivery system | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-11-04 | — | — | US | disclosed |
| WO-1996032951-A1 | CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER | GALIN MILES A (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | SIGMAR1 688/4885TAAR1 4388/4885SLC18A2 4779/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SIGMAR1 638/4885TAAR1 3894/4885SLC18A2 4404/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SIGMAR1 627/4885TAAR1 3837/4885SLC18A2 4418/4885 |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SIGMAR1 638/4885TAAR1 3894/4885SLC18A2 4404/4885 |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | VIP, MIF, MYLK | SIGMAR1 4794/4885TAAR1 4363/4885SLC18A2 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.